Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
BMC Cancer
    July 2026
  1. KURAL S, Kumar L, Pathak AK, Singh S, et al
    Non-invasive diagnostic evaluation of urinary exosomal let-7c cluster expression in bladder cancer using machine learning approaches.
    BMC Cancer. 2026 Jul 21. doi: 10.1186/s12885-026-16217.
    >> Share

  2. MOHANTY P, Subhangini M
    Immunohistochemical evaluation of molecular subtypes in muscle invasive bladder cancer with demographic correlation.
    BMC Cancer. 2026 Jul 10. doi: 10.1186/s12885-026-16476.
    >> Share

    June 2026
  3. HAO X, Ye C, Lai W, Xu J, et al
    Urologic malignancy in renal transplant recipients: Analysis of OPTN/UNOS data from 2000 to 2022.
    BMC Cancer. 2026;26:805.
    >> Share

  4. YI L, Ma Z, Zhang J, Zhan Y, et al
    A stratified urine-based molecular diagnostic and prognostic model for non-muscle-invasive bladder cancer management.
    BMC Cancer. 2026 Jun 22. doi: 10.1186/s12885-026-16361.
    >> Share

  5. ALTIN E, Dogan C, Arslan AI, Topkac EC, et al
    ELF-3 and TSC-1 as potential markers of recurrence in low-risk non-muscle-invasive bladder cancer.
    BMC Cancer. 2026 Jun 20. doi: 10.1186/s12885-026-16314.
    >> Share

  6. HU P, Wang C, Zeng X, Jin S, et al
    The predictive role of tertiary lymphoid structures in the prognosis and response to immunotherapy of bladder cancer patients: a systematic review and meta-analysis.
    BMC Cancer. 2026 Jun 13. doi: 10.1186/s12885-026-16326.
    >> Share

  7. WANG T, Jiang X
    Toripalimab plus disitamab vedotin versus tislelizumab-based combination in advanced urothelial carcinoma: a real-world comparative study.
    BMC Cancer. 2026;26:997.
    >> Share

  8. TAMBARO R, Calvanese G, Muto A, Formisano L, et al
    Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).
    BMC Cancer. 2026;26:956.
    >> Share

    May 2026
  9. CHEN C, Liu X, Xu A, Jiang N, et al
    Transcriptomic analysis of genes in bladder cancer patients with resistance to neoadjuvant chemoimmunotherapy.
    BMC Cancer. 2026 May 26. doi: 10.1186/s12885-026-16165.
    >> Share

  10. WANG Y, Ailiyaer A, Chen S, Wang W, et al
    Development and internal validation of an explainable machine-learning model to predict 3-year overall survival rate after radical cystectomy.
    BMC Cancer. 2026;26:813.
    >> Share

    April 2026
  11. RIZZO A, Ciccimarra F, de Casio Zequi S, Bove S, et al
    Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2(EV) project.
    BMC Cancer. 2026;26:756.
    >> Share

  12. WU Q, Lu P, Zhang X, Qing X, et al
    Persistent follicular cystitis following intravesical gemcitabine: a case series and literature review.
    BMC Cancer. 2026;26:680.
    >> Share

  13. TANUMA K, Shiga M, Sano K, Hamada K, et al
    Systemic administration of liposomal trehalose dimycolate induces NK1.1(+) cell mediated antitumor immunity in bladder cancer.
    BMC Cancer. 2026 Apr 1. doi: 10.1186/s12885-026-15951.
    >> Share

    March 2026
  14. KIM JH, Maeng S, Choi J, Lee CU, et al
    The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-guerin and an anti-PD-1 inhibitor in bladder cancer.
    BMC Cancer. 2026 Mar 29. doi: 10.1186/s12885-026-15890.
    >> Share

  15. HUO X, Qi J, Zhu Y, Song H, et al
    Integrative analysis of adenosine-related RNA modifications defines molecular subtypes of bladder cancer and identifies CES1 as a driver of tumor progression and immunotherapy resistance.
    BMC Cancer. 2026 Mar 25. doi: 10.1186/s12885-026-15897.
    >> Share

  16. FEKNER Z, Sieracka J, Dabrowski P, Kazmierski L, et al
    Mumio and bladder cancer: unlocking its potential in 3D cell culture.
    BMC Cancer. 2026 Mar 14. doi: 10.1186/s12885-026-15838.
    >> Share

    February 2026
  17. ZHANG L, Cao J, Gao Z, Han C, et al
    Correlations between metformin and prognosis and adverse reactions in patients undergoing radical cystectomy followed by adjuvant GC chemotherapy for bladder cancer.
    BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15806.
    >> Share

  18. GAO WB, Yu JJ
    Celldetect test performance in monitoring bladder cancer recurrence after transurethral resection.
    BMC Cancer. 2026 Feb 28. doi: 10.1186/s12885-026-15797.
    >> Share

  19. ZEBER-LUBECKA N, Bilski K, Dabrowska M, Goryca K, et al
    Sex-related differences in gene expression in early-stage bladder cancer revealed by whole-transcriptome sequencing.
    BMC Cancer. 2026 Feb 9. doi: 10.1186/s12885-026-15666.
    >> Share

  20. ISKENDER B, Sarihan M, Barlak BSR, Akpinar G, et al
    Conjoining cell reprogramming and mass spectrometry to identify the proteomic variations in the reprogrammed bladder cancer cells: finding cues of normalisation.
    BMC Cancer. 2026 Feb 6. doi: 10.1186/s12885-026-15634.
    >> Share

  21. OSAKA K, Kishida T, Umemoto S, Karashima T, et al
    Evaluation of variations in urine laminin-gamma2 monomer in non-muscle-invasive bladder cancer before and after transurethral resection of the bladder tumor.
    BMC Cancer. 2026 Feb 2. doi: 10.1186/s12885-026-15658.
    >> Share

    January 2026
  22. RAO XP, Zou XC, Yu ZJ, Yuan YY, et al
    Interpretable machine learning using CT radiomics predicts pathological upgrading after secondary resection in non-muscle-invasive bladder cancer.
    BMC Cancer. 2026 Jan 19. doi: 10.1186/s12885-026-15554.
    >> Share

    December 2025
  23. BLONDEAU A, Pitout A, Manuguerra A, Eschwege P, et al
    Sarcopenia measured by artificial intelligence as a predictor of overall survival in localized bladder cancer, a multicenter study.
    BMC Cancer. 2025 Dec 11. doi: 10.1186/s12885-025-15363.
    >> Share

  24. LAN K, Zhang Y, Luo Y, Hong T, et al
    Global, regional, and national burdens of bladder cancer attributable to high fasting plasma glucose from 1990 to 2021, with future forecasts to 2050: a systematic analysis for the global burden of disease study 2021.
    BMC Cancer. 2025 Dec 4. doi: 10.1186/s12885-025-15359.
    >> Share

  25. DU C, Wei W, Hu M, He J, et al
    Enhancing prediction accuracy for muscle invasion in bladder cancer using a dual-energy CT-based interpretable model incorporating habitat radiomics and deep learning.
    BMC Cancer. 2025;25:1842.
    >> Share

    November 2025
  26. YANG IN, Liang CA, Wu CC, Xu QS, et al
    Comprehensive surveillance of MicroRNA to discriminate between muscle-invasive and non-muscle-invasive urothelial carcinoma based on noninvasive urinary small RNA sequencing in Taiwanese patients.
    BMC Cancer. 2025;25:1900.
    >> Share

  27. ZHAO Y, Li P, Shen Z, Yao S, et al
    Elucidating a novel prognostic signature for bladder cancer by integrating hypoxia and lactate metabolism-related genes: comprehensive bioinformatics analyses and experimental evidence.
    BMC Cancer. 2025;25:1796.
    >> Share

  28. LEE SY, Lee YH, Kim TM, Ha US, et al
    TGF-beta signaling and tumor microenvironment dynamics in bladder cancer progression post-BCG therapy: a longitudinal single-nucleus RNA-seq study.
    BMC Cancer. 2025;25:1735.
    >> Share

  29. HU D, Liu H, Li M, Wu W, et al
    Prognostic value of prostate volume and nomograms for predicting recurrence in patients with non-muscle invasive bladder cancer: a multi-institutional study.
    BMC Cancer. 2025;25:1719.
    >> Share

  30. ZHAO Y, Ji Z, Sun W, Liu X, et al
    Plasma lipidomics for biomarker identification in non-muscle invasive bladder cancer.
    BMC Cancer. 2025;25:1702.
    >> Share

    October 2025
  31. ZHENG J, Lu S, Zhang Q, Zhang L, et al
    Development and external validation of a FISH-clinical nomogram for predicting overall survival in bladder cancer patients after radical cystectomy.
    BMC Cancer. 2025;25:1648.
    >> Share

  32. FANG C, Huang X, Dai J, He W, et al
    Retraction Note: The circular RNA circfarsa sponges microRNA-330-5p in tumor cells with bladder cancer phenotype.
    BMC Cancer. 2025;25:1613.
    >> Share

  33. LI W, Shi Y, Pu L, Zhang J, et al
    Shared decision-making in urinary reconstruction among radical cystectomy patients: a thematic analysis of patient and provider perspectives in China.
    BMC Cancer. 2025;25:1590.
    >> Share

  34. YEH CC, Tsai PC, Song YD, Low YS, et al
    Metformin as an anti-cancer agent against bladder cancer acts via PD-L1 downregulation in an orthotopic mouse model.
    BMC Cancer. 2025;25:1534.
    >> Share

  35. KANAAN MR, Schmitz J, Braesen JH, Kuczyk MA, et al
    Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the era of ADCs.
    BMC Cancer. 2025;25:1525.
    >> Share

  36. ABOULHODA BE, Omar AM, Elfarrash S, Alghamdi MA, et al
    Novel anticancer effect of substituted imidazole derivatives against urothelial carcinoma: integrating In vitro screening and molecular docking for target kinases.
    BMC Cancer. 2025;25:1524.
    >> Share

  37. CHEN B, Zhou Y, Li Z, Chen J, et al
    A study on predicting recurrence of non-muscle-invasive bladder cancer within 2 years using mp-MRI radiomics.
    BMC Cancer. 2025;25:1497.
    >> Share

    September 2025
  38. LIU S, Lei K, Li G, Zheng P, et al
    The integration of transcriptomics and metabolomics elucidates the antitumor mechanisms of mycophenolic acid in bladder cancer cells.
    BMC Cancer. 2025;25:1463.
    >> Share

  39. ZHANG J, Cheng X, Huang C, Xu Y, et al
    The diagnostic performance of a noninvasive urine-based methylation biomarkers Vimentin/POU4F2 to detect bladder carcinoma.
    BMC Cancer. 2025;25:1460.
    >> Share

  40. LI C, Liu J, Wang L, Xiong W, et al
    Mechanisms for fibrate lipid-lowering drugs in enhancing bladder cancer immunotherapy by inhibiting CD276 expression.
    BMC Cancer. 2025;25:1404.
    >> Share

    July 2025
  41. RAHATIJAFARABAD B, Poorkhani A, Esfandiari F, Sedaghat S, et al
    Trends in urinary tract cancer incidence in Golestan province, Iran: a 16-year population-based study.
    BMC Cancer. 2025;25:1227.
    >> Share

  42. LI J, Liang J, Xu Y, Tan W, et al
    Droplet digital PCR assay for precise determination of FRS2 gene copy number in bladder cancer.
    BMC Cancer. 2025;25:1211.
    >> Share

  43. WANG B, Gong Z, Su P, Zhen G, et al
    Multi-machine learning model based on radiomics features to predict prognosis of muscle-invasive bladder cancer.
    BMC Cancer. 2025;25:1116.
    >> Share

  44. HUANG L, Yan D, Ruan H, Lin Q, et al
    BAIAP2 as a driver of tumor progression in urothelial bladder cancer.
    BMC Cancer. 2025;25:1057.
    >> Share

    June 2025
  45. PAN Y, Shih HJ, Chuang SH, Chang CP, et al
    Effects of functional antioxidants on the expansion of gamma delta T-cells and their cellular cytotoxicity against bladder cancer cells.
    BMC Cancer. 2025;25:980.
    >> Share

    May 2025
  46. XU M, Zhou J, Lv J, Zhang Y, et al
    Tumor suppressing function of SLC16A7 in bladder cancer and its pan-cancer analysis.
    BMC Cancer. 2025;25:932.
    >> Share

  47. N S, Ps H, P R, Paul L, et al
    Novel Gene expression-based Risk Stratification tool predicts recurrence in Non-muscle invasive Bladder cancer.
    BMC Cancer. 2025;25:916.
    >> Share

  48. LAN T, Zhu Y, Zhong W, Tan Q, et al
    Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial.
    BMC Cancer. 2025;25:868.
    >> Share

    April 2025
  49. WANG X, Qu Y, Sun Y, Yang T, et al
    ATP6V0B promotes the tumorigenesis of bladder cancer by activating PAQR4/PI3K/AKT signaling.
    BMC Cancer. 2025;25:789.
    >> Share

  50. KITAHAMA K, Shigematsu Y, Sugawara E, Amori M, et al
    Clinicopathological characteristics of transcription factor-defined subtypes in bladder small cell carcinoma.
    BMC Cancer. 2025;25:766.
    >> Share

  51. QIU H, Deng X, Zha J, Wu L, et al
    Machine learning-based characterization of stemness features and construction of a stemness subtype classifier for bladder cancer.
    BMC Cancer. 2025;25:717.
    >> Share

  52. LI Z, Su M, Li Q, Zheng X, et al
    The role of CDK8 gene polymorphisms in bladder cancer susceptibility and prognosis: a study in the Chinese Han population.
    BMC Cancer. 2025;25:714.
    >> Share

  53. PLAGE H, Ahlburg V, Hofbauer S, Furlano K, et al
    Loss of chromosome Y is unrelated to the composition of the tumor microenvironment and patient prognosis in muscle-invasive urothelial bladder cancers.
    BMC Cancer. 2025;25:677.
    >> Share

    March 2025
  54. YANG H, Zhang T, Li Z, Cai Y, et al
    Risk factors for in-hospital venous thromboembolism in patients with bladder cancer: A retrospective single-center study.
    BMC Cancer. 2025;25:536.
    >> Share

  55. WAN S, Li KP, Chen SY, Wang CY, et al
    Single-cell sequencing combined with urinary multi-omics analysis reveals that the non-invasive biomarker PRDX5 regulates bladder cancer progression through ferroptosis signaling.
    BMC Cancer. 2025;25:533.
    >> Share

  56. DAI L, Ye K, Yao G, Lin J, et al
    Using machine learning for predicting cancer-specific mortality in bladder cancer patients undergoing radical cystectomy: a SEER-based study.
    BMC Cancer. 2025;25:523.
    >> Share

  57. SHENG Z, Xu J, Wang M, Xu X, et al
    The role of urinary microbiota in primary and recurrent bladder cancer: insights from a propensity score matching study.
    BMC Cancer. 2025;25:468.
    >> Share

    February 2025
  58. CAI J, Yan Z, Zhong Y, Li Y, et al
    Small non-coding RNA profiling in patients with non-muscle invasive bladder cancer.
    BMC Cancer. 2025;25:319.
    >> Share

  59. ZHENG Z, Dai F, Liu J, Zhang Y, et al
    Pathology-based deep learning features for predicting basal and luminal subtypes in bladder cancer.
    BMC Cancer. 2025;25:310.
    >> Share

  60. YAN L, Liang H, Qi T, Deng D, et al
    Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.
    BMC Cancer. 2025;25:297.
    >> Share

  61. WANG C, Li K, Huang R, Wan S, et al
    Urine proteomics-based analysis identifies CHI3L1 as an immune marker and potential therapeutic target for bladder cancer.
    BMC Cancer. 2025;25:271.
    >> Share

  62. LI Z, Wang Z, Wu J, Zhang F, et al
    Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients.
    BMC Cancer. 2025;25:268.
    >> Share

  63. LI KP, Wan S, Wang CY, Chen SY, et al
    Multi-omics analysis reveals the impact of YAP/TEAD4-mediated EIF5A1 expression on mitochondrial apoptosis and bladder cancer progression.
    BMC Cancer. 2025;25:234.
    >> Share

  64. LI P, Jing S, Kang Y, Feng B, et al
    Clinical outcomes of nephroureterectomy with bladder cuff excision or radical cystectomy for distal ureteral carcinoma invaded muscle of the ureteral orifice.
    BMC Cancer. 2025;25:221.
    >> Share

  65. FURUKAWA J, Kakei Y, Murakami S, Kita H, et al
    Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial.
    BMC Cancer. 2025;25:195.
    >> Share

    January 2025
  66. CHEN T, Zou X, Li Y, Peng L, et al
    Evaluation of the association between lymph node ratio and long-term survival in patients after surgery for lymph node-positive bladder cancer: a SEER population-based study with external validation.
    BMC Cancer. 2025;25:135.
    >> Share

    November 2024
  67. SCHUCK S, Loussikian P, Mebarki A, Malaab J, et al
    Perceived unmet needs and impact on quality of life of patients living with advanced bladder cancer and their caregivers: results of a social media listening study conducted in five European countries.
    BMC Cancer. 2024;24:1444.
    >> Share

    October 2024
  68. FUKUMOTO W, Okamura S, Tamai M, Arima J, et al
    Development of a novel treatment based on PKMYT1 inhibition for cisplatin-resistant bladder cancer with miR-424-5p-dependent cyclin E1 amplification.
    BMC Cancer. 2024;24:1333.
    >> Share

  69. KARLSSON P, Nygren-Bonnier M, Torikka S, Porserud A, et al
    Patients experiences of an exercise intervention in primary care following robot-assisted radical cystectomy due to bladder cancer: a qualitative study.
    BMC Cancer. 2024;24:1306.
    >> Share

  70. SONG J, Sun X, Wang T, Li C, et al
    Circulating levels of cytokines and risk of urologic cancers: a two-sample Mendelian randomization study.
    BMC Cancer. 2024;24:1261.
    >> Share

  71. YAO Z, Li Y, Ding Y, Hou Y, et al
    Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters >/=3cm compared to transurethral resection: a non-randomized controlled study.
    BMC Cancer. 2024;24:1239.
    >> Share

    September 2024
  72. PALACKA P, Holickova A, Roska J, Makovicky P, et al
    Prognostic value of nucleotide excision repair and translesion DNA synthesis proteins in muscle-infiltrating bladder carcinoma.
    BMC Cancer. 2024;24:1103.
    >> Share

    August 2024
  73. FAN Z, Liu Y, Wang X, Xu Y, et al
    APOL6 predicts immunotherapy efficacy of bladder cancer by ferroptosis.
    BMC Cancer. 2024;24:1046.
    >> Share

  74. CHEN D, Cao H, Zheng X, Wang H, et al
    Immune checkpoint gene signature assesses immune infiltration profiles in bladder cancer and identifies KRT23 as an immunotherapeutic target.
    BMC Cancer. 2024;24:1024.
    >> Share

  75. BOTROUS S, Elmaghraby A, Achy SE, Mustafa Y, et al
    Artemisinin pre-treatment fore cisplatin dosage enhances high grade urothelial carcinoma treatment in male albino mice via reverse gene expression modulation of FGFR3, HRAS, P53 and KDM6A.
    BMC Cancer. 2024;24:971.
    >> Share

  76. HAO S, Yang Z, Wang G, Cai G, et al
    Development of prognostic model incorporating a ferroptosis/cuproptosis-related signature and mutational landscape analysis in muscle-invasive bladder cancer.
    BMC Cancer. 2024;24:958.
    >> Share

  77. LIU R, Yang T, Huang J, Xiao Z, et al
    Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
    BMC Cancer. 2024;24:947.
    >> Share

    July 2024
  78. CICIN I, Plimack ER, Gurney H, Leibowitz R, et al
    Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study.
    BMC Cancer. 2024;23.
    >> Share

  79. PORSERUD A, Karlsson P, Aly M, Rydwik E, et al
    Effects of an exercise intervention in primary care after robot-assisted radical cystectomy for urinary bladder cancer: a randomised controlled trial.
    BMC Cancer. 2024;24:891.
    >> Share

  80. IQBAL MS, Sardar N, Peng K, Almutairi LA, et al
    Association between CYP1A2 gene variants -163 C/A (rs762551) and -3860 G/A (rs2069514) and bladder cancer susceptibility.
    BMC Cancer. 2024;24:880.
    >> Share

  81. MOHAMED AH, Mohamed KA, Kayacan E, Nur Y, et al
    Clinical characteristics and factors associated with survival rate of patients with non-muscle invasive bladder cancer attending at a Tertiary Hospital in Somalia.
    BMC Cancer. 2024;24:839.
    >> Share

    June 2024
  82. ZHANG X, Hong B, Li H, Zhao J, et al
    Basement membrane-related MMP14 predicts poor prognosis and response to immunotherapy in bladder cancer.
    BMC Cancer. 2024;24:746.
    >> Share

  83. MENG H, Yang R, Lin Q, Du W, et al
    Isorhapontigenin inhibition of basal muscle-invasive bladder cancer attributed to its downregulation of SNHG1 and DNMT3b.
    BMC Cancer. 2024;24:737.
    >> Share

  84. JI J, Zhang T, Zhu L, Yao Y, et al
    Using machine learning to develop preoperative model for lymph node metastasis in patients with bladder urothelial carcinoma.
    BMC Cancer. 2024;24:725.
    >> Share

    March 2024
  85. LI X, Liang Z, Pan J, Zhang M, et al
    Identification of BACH1-IT2-miR-4786-Siglec-15 immune suppressive axis in bladder cancer.
    BMC Cancer. 2024;24:328.
    >> Share

    February 2024
  86. HUANG LH, Chen CS, Li JR, Chiu KY, et al
    The impact of squamous cell transformation on the prognosis of patients treated with radical nephroureterectomy.
    BMC Cancer. 2024;24:247.
    >> Share

  87. ZHANG J, Yang M, Wei D, Zhang D, et al
    The efficacy and safety of tislelizumab combined with gemcitabine plus cisplatin in the treatment of postoperative patients with muscle-invasive upper tract urothelial carcinoma.
    BMC Cancer. 2024;24:202.
    >> Share

  88. YANG M, Zhang J, Wei D, Yu T, et al
    Inflammatory markers predict survival in patients with postoperative urothelial carcinoma receiving tislelizumab (PD-1 inhibitor) adjuvant therapy.
    BMC Cancer. 2024;24:196.
    >> Share

    January 2024
  89. PAN DL, Zhang LF, Li XJ, Zhang KP, et al
    Feasibility and safety of laparoscopic radical cystectomy for male octogenarians with muscle-invasive bladder cancer.
    BMC Cancer. 2024;24:159.
    >> Share

  90. VERGHOTE F, Van Praet C, Berquin C, Lumen N, et al
    Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice.
    BMC Cancer. 2024;24:160.
    >> Share

  91. JING S, Yang E, Luo Z, Zhang Y, et al
    Perioperative outcomes and continence following robotic-assisted radical cystectomy with mainz pouch II urinary diversion in patients with bladder cancer.
    BMC Cancer. 2024;24:127.
    >> Share

    November 2023
  92. GORE JL, Wolff EM, Comstock BA, Follmer KM, et al
    Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
    BMC Cancer. 2023;23:1127.
    >> Share

  93. ROUSSOT N, Fumet JD, Limagne E, Thibaudin M, et al
    A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
    BMC Cancer. 2023;23:1080.
    >> Share

  94. LU L, Chen C, Cheng H, Ding H, et al
    Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1066.
    >> Share

    October 2023
  95. CHEN JX, Huang WT, Zhang QY, Deng CE, et al
    The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:1018.
    >> Share

  96. LI Y, Xu K, Zhang Y, Mao H, et al
    Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    BMC Cancer. 2023;23:1021.
    >> Share

  97. LUO L, Xie Q, Wu Y, Li P, et al
    Circular RNA CCT3 is a unique molecular marker in bladder cancer.
    BMC Cancer. 2023;23:977.
    >> Share

  98. HE Q, Wu S, Zhou Y, Liu Y, et al
    Genetic factors, adherence to healthy lifestyle behaviors, and risk of bladder cancer.
    BMC Cancer. 2023;23:965.
    >> Share

  99. ZHENHAI Z, Qi C, Shuchao Z, Zhongqi W, et al
    MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation.
    BMC Cancer. 2023;23:956.
    >> Share

  100. TANABE K, Nakanishi Y, Okubo N, Matsumoto S, et al
    Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria II.
    BMC Cancer. 2023;23:940.
    >> Share

  101. WANG Y, Pan J, An F, Chen K, et al
    GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
    BMC Cancer. 2023;23:925.
    >> Share

    September 2023
  102. ALT M, Stecca C, Lin Y, Kazeem G, et al
    Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
    BMC Cancer. 2023;23:919.
    >> Share

  103. TSAI TH, Su PJ, Huang SY, Kuo MC, et al
    The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.
    BMC Cancer. 2023;23:871.
    >> Share

  104. NASR S, Haddad FG, Khazen J, Kattan J, et al
    PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience.
    BMC Cancer. 2023;23:817.
    >> Share

    August 2023
  105. CAI Y, Cheng Y, Wang Z, Li L, et al
    A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    BMC Cancer. 2023;23:725.
    >> Share

  106. JIANG Y, Zhu C, Huang H, Huang G, et al
    TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
    BMC Cancer. 2023;23:716.
    >> Share

    July 2023
  107. LI W, Liu Z, Jin K, Shao F, et al
    Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:661.
    >> Share

    June 2023
  108. KERZELI IK, Kostakis A, Turker P, Malmstrom PU, et al
    Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.
    BMC Cancer. 2023;23:605.
    >> Share

  109. LIANG PI, Lai HY, Chan TC, Li WM, et al
    Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
    BMC Cancer. 2023;23:599.
    >> Share

  110. LIU J, Wu P, Lai S, Wang J, et al
    Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning.
    BMC Cancer. 2023;23:574.
    >> Share

  111. NISHIYAMA H, Tanaka Y, Hamada M, Ozaki M, et al
    Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
    BMC Cancer. 2023;23:565.
    >> Share

  112. RUTTEN VC, Salhi Y, Robbrecht GJ, de Wit R, et al
    The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial.
    BMC Cancer. 2023;23:539.
    >> Share

  113. KOLL FJ, Doring C, Olah C, Szarvas T, et al
    Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
    BMC Cancer. 2023;23:504.
    >> Share

    April 2023
  114. HUI P, Ni F, Zheng L, Jia L, et al
    Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer.
    BMC Cancer. 2023;23:355.
    >> Share

  115. TANG Y, Lei Y, Gao P, Jia J, et al
    Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker.
    BMC Cancer. 2023;23:328.
    >> Share

  116. YANG X, Zhang S, Cui Y, Li Y, et al
    Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial.
    BMC Cancer. 2023;23:320.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016